| Name | Title | Contact Details |
|---|
Heart Force Medical Inc. (HFM), a private company, has invented and has patents pending for the digital Ballistocardiograph (dBG(TM)). The dBG 300, which is already approved in Canada and the United States, captures the movement of the heart during each cardiac cycle (heart beat). This movement (acceleration and force) is sensed by an accelerometer aligned to the three principal axes and displayed on a computer screen using HFM's proprietary software. Preliminary evaluation has determined that a 10-30 second recording of the dBG waveform is sufficient for a detailed analysis of cardiac performance. The Heart Force dBG 300 device is a non-invasive, standalone, portable unit and contains sophisticated digital sensors and proprietary software.
ConcertoCare is one of the nation`s leading risk-based health care companies focused on providing integrated care for seniors where they are best served: in their homes. ConcertoCare`s programs are designed for seniors with the same core, in-home care model and composed collaboratively with patients. The ConcertoCare model improves overall health quality and outcomes with a proven track record of reducing hospital admits by 47%, readmits by 40% and ER visits by 16% while achieving an increase of 38% in annual wellness visits for the most vulnerable patient populations in the U.S., benefiting patients, payers and provider networks alike. The programs are supported by a combination of in-home medical, behavioral and social services and enhanced via advanced proprietary technologies.
Dickinson Mental Health Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Dickinson Mental Health Center is based in Ridgway, PA. You can find more information on Dickinson Mental Health Center at www.dmhc.org
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Brisar Delvco is a Paterson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.